中文 | English     

B-hPD-1/hLAG3 mice

2017-08-04 14:10:20.0

Strain description


Strain Name C57BL/6-Pdcd1tm1(hPDCD1)Lag3tm1(hLAG3)/Bcgen Common Name B-hPD-1/hLAG3 mice
Background C57BL/6 Catalog number B-DM-005
Catalog number (Males) BDM005M Catalog number (Females) BDM005F

Related Genes


PD-1(Programmed death-1) ;

LAG3(Lymphocyte activation gene 3,CD223)


Targeting strategy

打靶策略.png


Protein expression analysis 

图1.png





Fig 1. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hLAG3 mice were analyzed by flow cytometry. 

Mouse LAG3+ T cells were detected in both WT C57BL/6 and the homozygous B-hPD-1/hLAG3 mice, while human LAG3+ T cells were detected in the homozygous B-hPD-1/hLAG3 mice. This might result from the cross-recognition of hLAG3 by anti-mLAG3 antibodies.




图2.png





Fig 2. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hLAG3 mice were analyzed by flow cytometry. 

Mouse PD-1+ T cells were detected in the WT C57BL/6 mice, while human PD-1+ T cells were detected in the homozygous B-hPD-1/hLAG3 mice.






图片.png






Fig 3. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hLAG3 mice were analyzed by flow cytometry. 

Mouse PD-1+/LAG3+ T cells were detected in the WT C57BL/6 mice, while mouse LAG3+ T cells were detected in the homozygous B-hPD-1/hLAG3 mice, which might result from the cross-recognition of hLAG3 by anti-mLAG3 antibodies.





图片.png







Fig 4. Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hLAG3 mice were analyzed by flow cytometry. 

Human PD-1+/LAG3+ T cells were detected in homozygous B-hPD-1/hLAG3 mice.







Combination therapy of PD-1(Keytruda) Ab and LAG3 Ab

图5.png

Fig 5. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hLAG3 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=6). Anti-hLAG3 antibody shows no inhibitory effects, while the anti-hPD-1 antibody Keytruda shows modest tumor growth inhibition. On the other hand, combination of anti-hLAG3 antibody and the antihPD-1 antibody Keytruda shows more significant inhibition when compared to single Ab treatment. B-hPD-1 /hLAG3 mouse model is a powerful tool for in vivo efficacy evaluation of hPD-1 and hLAG3 antibody combination therapy. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.




Copyright © BIOCYTOGEN LLC. 2017 All Rights Reserved.